resTORbio is a biopharmaceutical company developing therapeutics for treating age-related diseases that is headquartered in Boston, Massachusetts and was founded in 2016 by Chen Schor and Joan Mannick.
On January 1, 2017 resTORbio completed their series A funding round with $25 million in funding from PureTech Health.
On November 30, 2017 resTORbio completed their series B funding rounds with $40 million in funding from OrbiMed (lead investor), Rock Springs Capital, Recharge Capital, Quan Capital, Nest.Bio Ventures, and Fidelity Management and Research Company.
Timeline
Funding rounds
People
Chen Schor
Co-Founder, President and CEO
Joan Mannick
Co-Founder, Chief Medical Officer
Sarb Shergill
Vice President of Clinical Operations
Further reading
resTORbio launches Phase Ib/IIa trial of RTB101 to treat Parkinson's
Drugdevelopment-technology
Web